DexCom, Inc.

NASDAQ:DXCM

Medical - Devices

Healthcare
$82.52 +1.27%

+$0.90 today

Market cap
$30.78B
Beta
1.44
P/E (TTM)
29.9
EPS (TTM)
$2.42
52W Low $54.11High $89.98

Volume 4.25M

Average 5.43M

DXCM Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

DexCom, Inc.NASDAQ: DXCM

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $358.7M rose 9.4% year over year, ahead of the +7.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.

Context

  • Selling, general & admin amounted to 27.7% of revenue in FY2025, down 4.2 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 21 analysts of $1.67B (+29.6%) for the fiscal year ending Dec 2026, a step up from the +0.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$358.7M+2.6% QoQ
Last fiscal yearDec 2025
$1.29B+0.4% YoY
LTMJun 2026
$1.36B+7.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.4%+28.3%+19.0 pp
1 year+0.4%+29.6%+29.2 pp
3-year CAGR+8.6%+16.6%+8.0 pp
5-year CAGR+14.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
1.29B USD
Year-over-year change
+0.4%
4-year CAGR
+12.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How DXCM compares with its peers on the latest reported figures

  • DXCM's LTM Jun 2026 selling, general & admin of $1.36B is the highest of the 7 companies compared; the peer median is $270.06M.
  • Its year-over-year change of +7.0% is the 4th highest of 6, against a peer median of +29.1%.
  • Selling, general & admin amounts to 27.4% of revenue for DXCM, versus a peer median of 68.0%.
DXCM Competitors Peer median
Selling, General & Admin for DXCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DXCMDexCom, Inc.LTM Jun 2026$1.36B +7.0%+8.6%27.4%
PODDInsulet CorporationLTM Jun 2026$1.31B +29.1%+25.6%42.9%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$1.24B —+7.2%38.4%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$437.36M +5.8%+9.0%42.6%
BBNXBeta Bionics, Inc.LTM Mar 2026$102.76M +61.1%+40.3%93.2%
SENSSenseonics Holdings, Inc.LTM Mar 2026$74.99M +121.9%+18.4%184.2%
DRIODarioHealth Corp.LTM Mar 2026$34.47M -17.2%-8.8%162.7%
MMEDVMiniMed Group, Inc.—— ———
Peer median (excluding DXCM) $270.06M+29.1%+13.7%68.0%

Competitors are the stored peer set for DXCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.45B2.91B3.62B4.03B4.66B
Cost of Revenue768M1.03B1.33B1.59B1.86B
Gross Profit1.68B1.88B2.29B2.44B2.8B
Gross Margin68.6%64.7%63.2%60.5%60.1%
Research & Development604.2M484.2M505.8M552.4M599.1M
Selling, General & Admin810.5M1.01B1.19B1.29B1.29B
Operating Expenses1.41B1.49B1.69B1.84B1.89B
Depreciation & Amortization102M155.9M186M217.7M251.8M
EBITDA377.6M565.3M916.7M945.7M1.36B
EBITDA Margin15.4%19.4%25.3%23.4%29.1%
Operating Income265.8M391.2M597.7M600M911.8M
Operating Margin10.9%13.4%16.5%14.9%19.6%
Interest Income1.7M23.8M135M134.2M112.7M
Interest Expense18.8M18.6M20.3M19M18.3M
Other Income / Expenses(9M)(400K)112.7M109M176.6M
Income Before Tax256.8M390.8M710.4M709M1.09B
Pre-Tax Margin10.5%13.4%19.6%17.6%23.3%
Income Tax Expense39.9M49.6M168.9M132.8M252.1M
Net Income216.9M341.2M541.5M576.2M836.3M
Net Margin8.9%11.7%14.9%14.3%17.9%
EPS (Basic)0.560.881.441.462.14
EPS (Diluted)0.510.801.301.422.09
Weighted Avg Shares386.9M389.4M386M404.63M390.2M
Weighted Avg Shares (Diluted)428.8M427.5M425.5M412.7M405.5M

DexCom, Inc.

NASDAQ:DXCM

Intrinsic Alpha fair value

Locked

Current Price

$82.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.